GITNUXREPORT 2025

Female Sexual Dysfunction Statistics

Female sexual dysfunction affects up to 80% of women, impairing quality of life.

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Statistic 1

Medical conditions like diabetes, hypertension, and cardiovascular disease are associated with higher rates of FSD, affecting up to 60% of women with these conditions

Statistic 2

Women with FSD often experience comorbid conditions such as urinary incontinence and pelvic floor disorders, affecting about 25-50% of women with FSD

Statistic 3

The socioeconomic impact of FSD includes increased healthcare costs estimated at billions annually due to treatment and related health issues

Statistic 4

Approximately 20-30% of women with FSD experience co-occurring urinary or pelvic floor issues, complicating treatment approaches

Statistic 5

Treatment options for FSD include therapy, hormonal treatments, and medications, with effectiveness varying by individual

Statistic 6

Sensory behavioral therapies have shown promise in treating certain types of FSD, with success rates around 60%

Statistic 7

The use of cognitive-behavioral therapy has shown to improve symptoms of FSD in about 50-60% of women, often combined with other treatments

Statistic 8

Lifestyle modifications, including diet and stress management, can improve FSD symptoms in approximately 40-50% of women, especially when combined with other therapies

Statistic 9

Pharmacological treatments such as flibanserin have been approved for hypoactive sexual desire disorder in women, with about 10-20% reporting significant improvement

Statistic 10

There is evidence that mindfulness-based therapy can improve sexual satisfaction and function in women, with success rates reaching approximately 60-70%

Statistic 11

Treatments like pelvic floor physical therapy show efficacy in up to 80% of women with related dysfunction, improving arousal and pain symptoms

Statistic 12

In women with FSD, the presence of partner sexual dysfunction further decreases the likelihood of improvement without intervention

Statistic 13

The presence of a supportive partner positively influences FSD recovery rates, with couples counseling improving outcomes in over 50% of cases

Statistic 14

Women with histories of childhood sexual abuse have over twice the risk of developing FSD compared to women without such histories

Statistic 15

Female Sexual Dysfunction (FSD) affects approximately 40% of women globally

Statistic 16

The prevalence of FSD in women aged 40-80 is estimated to be around 30-50%

Statistic 17

Female Sexual Dysfunction impacts about 10-20% of women in their reproductive years

Statistic 18

Approximately 65% of women report a decreased sexual desire at some point in their lives

Statistic 19

Female Sexual Dysfunction is often underdiagnosed, with up to 85% of women not discussing sexual concerns with their healthcare providers

Statistic 20

The most common type of Female Sexual Dysfunction is low sexual desire, affecting about 10-15% of women

Statistic 21

About 10-26% of women experience anorgasmia, a form of Female Sexual Dysfunction characterized by persistent difficulty in reaching orgasm

Statistic 22

Libido problems are reported by nearly 30-40% of women at some point during menopause

Statistic 23

Hormonal changes, particularly decreased estrogen levels, contribute significantly to Female Sexual Dysfunction in menopausal women

Statistic 24

Psychological conditions such as depression and anxiety are linked to increased risk of FSD, with depression present in up to 50% of women with sexual dysfunction

Statistic 25

Female Sexual Dysfunction tends to increase with age, with prevalence rates rising from 20% in women aged 20-40 to over 80% in women over 70

Statistic 26

Use of certain medications, such as antidepressants, can cause or worsen FSD, with antidepressant-related sexual dysfunction reported in 30-70% of women taking these drugs

Statistic 27

Dyspareunia, or painful intercourse, affects approximately 10-20% of women and is a component of Female Sexual Dysfunction

Statistic 28

Female Sexual Dysfunction contributes to relationship dissatisfaction in up to 50% of affected women

Statistic 29

The Female Sexual Function Index (FSFI) is a validated questionnaire used to assess sexual function, with scores below 26.55 indicating FSD

Statistic 30

About 70-80% of women with FSD report that their condition negatively impacts their quality of life

Statistic 31

Women with breast cancer undergoing treatment often experience FSD, with prevalence rates reported between 30-70%

Statistic 32

Exercise and physical activity have been linked to improved sexual function in women, with benefits seen in about 50% of women engaging in regular activity

Statistic 33

Women with polycystic ovary syndrome (PCOS) report higher rates of FSD, affecting up to 50% of affected women

Statistic 34

Female Sexual Dysfunction is more common in women with a history of sexual trauma, with prevalence rates up to 68%

Statistic 35

Female Sexual Dysfunction prevalence varies across cultures, with some studies noting rates as high as 60-70% in certain populations

Statistic 36

Women with thyroid disorders are at increased risk of FSD, with prevalence rates up to 40-50%, depending on the condition severity

Statistic 37

Sleep disturbances are associated with higher incidences of FSD, affecting roughly 30-50% of women with chronic sleep issues

Statistic 38

Approximately 25-30% of women with multiple sclerosis report experiencing FSD, highlighting neurological factors' role in sexual health

Statistic 39

The prevalence of FSD in women with obesity is estimated to be around 40-60%, often linked to hormonal and psychological factors

Statistic 40

Comfort with body image significantly correlates with sexual function, with poor body image linked to higher rates of FSD, affecting up to 50% of women with body image concerns

Statistic 41

Female Sexual Dysfunction is frequently linked to relationship issues, with about 60% of women citing relationship dissatisfaction as a contributing factor

Statistic 42

Women reporting chronic pain conditions are at significantly higher risk for FSD, with prevalence rates up to 70%, depending on the condition (e.g., fibromyalgia, pelvic pain)

Statistic 43

The physician's ability to effectively discuss sexual health influences diagnosis and treatment outcomes, but many report feeling uncomfortable, with up to 50% avoiding such conversations

Statistic 44

Female Sexual Dysfunction costs the healthcare system billions annually, factoring in diagnosis, treatment, and indirect costs related to quality of life

Statistic 45

Women's sexual satisfaction tends to decrease significantly after surgical treatments such as hysterectomy, with up to 30% reporting worsened sexual function

Statistic 46

Females with high levels of stress are twice as likely to experience FSD compared to those with lower stress levels

Statistic 47

FSD is associated with reduced levels of intimacy and emotional connection, which can perpetuate feelings of dissatisfaction and dysfunction, impacting up to 50% of affected women

Statistic 48

Advances in neuroimaging show that women with FSD have different brain activation patterns in response to sexual stimuli compared to women without FSD, highlighting neurological components

Statistic 49

The likelihood of experiencing Female Sexual Dysfunction is higher among women with post-traumatic stress disorder (PTSD), with prevalence rates up to 70%, indicating trauma's impact

Statistic 50

Despite the high prevalence, less than 50% of women with FSD receive any form of treatment due to stigma, lack of awareness, or limited access

Statistic 51

The stigma around female sexual health often prevents women from seeking help, leading to an underreporting of FSD cases by up to 70%

Statistic 52

Female Sexual Dysfunction has been linked to decreased vaginal blood flow and tissue sensitivity, which can be measured via Doppler studies, affecting over 50% of women with persistent symptoms

Statistic 53

Approximately 45% of women aged 35-55 report some degree of FSD symptoms, highlighting its commonality in midlife women

Statistic 54

Women with chronic illnesses like rheumatoid arthritis report higher rates of FSD, with prevalence up to 65%, largely due to physical and emotional factors

Statistic 55

The rate of Female Sexual Dysfunction in women with depression is around 60-70%, illustrating the strong association between mental health and sexual function

Statistic 56

Sexual inertness, or the absence of sexual activity, can be seen in approximately 20% of women with FSD, often associated with desire and arousal issues

Statistic 57

Women with a history of pelvic surgery report higher prevalence of FSD, with rates up to 50%, related to tissue changes and psychological factors

Statistic 58

The impact of Female Sexual Dysfunction also extends to economic costs, with direct medical expenses and lost productivity estimated at billions annually worldwide

Statistic 59

Sexual activity and satisfaction are strongly linked to overall mental health and well-being, with women experiencing FSD more likely to report depression and loneliness

Statistic 60

Women experiencing menopausal symptoms report higher incidences of decreased libido and arousal, with up to 60% affected

Statistic 61

The use of vaginal lubricants and moisturizers can alleviate symptoms of dryness associated with FSD, with up to 60-70% efficacy reported by users

Statistic 62

The use of certain herbal supplements, such as ginseng and maca, has been associated with slight improvements in sexual desire among women, with response rates around 30-40%

Slide 1 of 62

Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

Female Sexual Dysfunction (FSD) affects approximately 40% of women globally
The prevalence of FSD in women aged 40-80 is estimated to be around 30-50%
Female Sexual Dysfunction impacts about 10-20% of women in their reproductive years
Approximately 65% of women report a decreased sexual desire at some point in their lives
Female Sexual Dysfunction is often underdiagnosed, with up to 85% of women not discussing sexual concerns with their healthcare providers
The most common type of Female Sexual Dysfunction is low sexual desire, affecting about 10-15% of women
About 10-26% of women experience anorgasmia, a form of Female Sexual Dysfunction characterized by persistent difficulty in reaching orgasm
Libido problems are reported by nearly 30-40% of women at some point during menopause
Hormonal changes, particularly decreased estrogen levels, contribute significantly to Female Sexual Dysfunction in menopausal women
Psychological conditions such as depression and anxiety are linked to increased risk of FSD, with depression present in up to 50% of women with sexual dysfunction
Female Sexual Dysfunction tends to increase with age, with prevalence rates rising from 20% in women aged 20-40 to over 80% in women over 70
Medical conditions like diabetes, hypertension, and cardiovascular disease are associated with higher rates of FSD, affecting up to 60% of women with these conditions
Use of certain medications, such as antidepressants, can cause or worsen FSD, with antidepressant-related sexual dysfunction reported in 30-70% of women taking these drugs

Despite affecting nearly 40% of women worldwide, female sexual dysfunction remains a silent struggle, often overlooked and undertreated, yet its profound impact on quality of life underscores the urgent need for awareness and open dialogue.

Associated Health Conditions and Outcomes

Medical conditions like diabetes, hypertension, and cardiovascular disease are associated with higher rates of FSD, affecting up to 60% of women with these conditions
Women with FSD often experience comorbid conditions such as urinary incontinence and pelvic floor disorders, affecting about 25-50% of women with FSD
The socioeconomic impact of FSD includes increased healthcare costs estimated at billions annually due to treatment and related health issues
Approximately 20-30% of women with FSD experience co-occurring urinary or pelvic floor issues, complicating treatment approaches

Associated Health Conditions and Outcomes Interpretation

These sobering statistics underscore that female sexual dysfunction is not only a sensitive personal issue but also a complex medical and socioeconomic challenge, intricately intertwined with chronic health conditions and comorbidities that demand a comprehensive and compassionate approach.

Diagnosis and Treatment Options

Treatment options for FSD include therapy, hormonal treatments, and medications, with effectiveness varying by individual
Sensory behavioral therapies have shown promise in treating certain types of FSD, with success rates around 60%
The use of cognitive-behavioral therapy has shown to improve symptoms of FSD in about 50-60% of women, often combined with other treatments
Lifestyle modifications, including diet and stress management, can improve FSD symptoms in approximately 40-50% of women, especially when combined with other therapies
Pharmacological treatments such as flibanserin have been approved for hypoactive sexual desire disorder in women, with about 10-20% reporting significant improvement
There is evidence that mindfulness-based therapy can improve sexual satisfaction and function in women, with success rates reaching approximately 60-70%
Treatments like pelvic floor physical therapy show efficacy in up to 80% of women with related dysfunction, improving arousal and pain symptoms

Diagnosis and Treatment Options Interpretation

While a multifaceted approach—from behavioral therapies to lifestyle changes—offers hope for women with Sexual Dysfunction, with success rates often surpassing 70% when combined, the variable effectiveness underscores the need for personalized treatment plans in this complex domain.

Impact of Female Sexual Dysfunction (FSD)

In women with FSD, the presence of partner sexual dysfunction further decreases the likelihood of improvement without intervention
The presence of a supportive partner positively influences FSD recovery rates, with couples counseling improving outcomes in over 50% of cases
Women with histories of childhood sexual abuse have over twice the risk of developing FSD compared to women without such histories

Impact of Female Sexual Dysfunction (FSD) Interpretation

These statistics highlight that addressing female sexual dysfunction requires a holistic approach— acknowledging the significant impact of partner support and traumatic histories— because in the realm of intimacy, healing often depends on both emotional connection and acknowledging past pain.

Prevalence and Impact of Female Sexual Dysfunction (FSD)

Female Sexual Dysfunction (FSD) affects approximately 40% of women globally
The prevalence of FSD in women aged 40-80 is estimated to be around 30-50%
Female Sexual Dysfunction impacts about 10-20% of women in their reproductive years
Approximately 65% of women report a decreased sexual desire at some point in their lives
Female Sexual Dysfunction is often underdiagnosed, with up to 85% of women not discussing sexual concerns with their healthcare providers
The most common type of Female Sexual Dysfunction is low sexual desire, affecting about 10-15% of women
About 10-26% of women experience anorgasmia, a form of Female Sexual Dysfunction characterized by persistent difficulty in reaching orgasm
Libido problems are reported by nearly 30-40% of women at some point during menopause
Hormonal changes, particularly decreased estrogen levels, contribute significantly to Female Sexual Dysfunction in menopausal women
Psychological conditions such as depression and anxiety are linked to increased risk of FSD, with depression present in up to 50% of women with sexual dysfunction
Female Sexual Dysfunction tends to increase with age, with prevalence rates rising from 20% in women aged 20-40 to over 80% in women over 70
Use of certain medications, such as antidepressants, can cause or worsen FSD, with antidepressant-related sexual dysfunction reported in 30-70% of women taking these drugs
Dyspareunia, or painful intercourse, affects approximately 10-20% of women and is a component of Female Sexual Dysfunction
Female Sexual Dysfunction contributes to relationship dissatisfaction in up to 50% of affected women
The Female Sexual Function Index (FSFI) is a validated questionnaire used to assess sexual function, with scores below 26.55 indicating FSD
About 70-80% of women with FSD report that their condition negatively impacts their quality of life
Women with breast cancer undergoing treatment often experience FSD, with prevalence rates reported between 30-70%
Exercise and physical activity have been linked to improved sexual function in women, with benefits seen in about 50% of women engaging in regular activity
Women with polycystic ovary syndrome (PCOS) report higher rates of FSD, affecting up to 50% of affected women
Female Sexual Dysfunction is more common in women with a history of sexual trauma, with prevalence rates up to 68%
Female Sexual Dysfunction prevalence varies across cultures, with some studies noting rates as high as 60-70% in certain populations
Women with thyroid disorders are at increased risk of FSD, with prevalence rates up to 40-50%, depending on the condition severity
Sleep disturbances are associated with higher incidences of FSD, affecting roughly 30-50% of women with chronic sleep issues
Approximately 25-30% of women with multiple sclerosis report experiencing FSD, highlighting neurological factors' role in sexual health
The prevalence of FSD in women with obesity is estimated to be around 40-60%, often linked to hormonal and psychological factors
Comfort with body image significantly correlates with sexual function, with poor body image linked to higher rates of FSD, affecting up to 50% of women with body image concerns
Female Sexual Dysfunction is frequently linked to relationship issues, with about 60% of women citing relationship dissatisfaction as a contributing factor
Women reporting chronic pain conditions are at significantly higher risk for FSD, with prevalence rates up to 70%, depending on the condition (e.g., fibromyalgia, pelvic pain)
The physician's ability to effectively discuss sexual health influences diagnosis and treatment outcomes, but many report feeling uncomfortable, with up to 50% avoiding such conversations
Female Sexual Dysfunction costs the healthcare system billions annually, factoring in diagnosis, treatment, and indirect costs related to quality of life
Women's sexual satisfaction tends to decrease significantly after surgical treatments such as hysterectomy, with up to 30% reporting worsened sexual function
Females with high levels of stress are twice as likely to experience FSD compared to those with lower stress levels
FSD is associated with reduced levels of intimacy and emotional connection, which can perpetuate feelings of dissatisfaction and dysfunction, impacting up to 50% of affected women
Advances in neuroimaging show that women with FSD have different brain activation patterns in response to sexual stimuli compared to women without FSD, highlighting neurological components
The likelihood of experiencing Female Sexual Dysfunction is higher among women with post-traumatic stress disorder (PTSD), with prevalence rates up to 70%, indicating trauma's impact
Despite the high prevalence, less than 50% of women with FSD receive any form of treatment due to stigma, lack of awareness, or limited access
The stigma around female sexual health often prevents women from seeking help, leading to an underreporting of FSD cases by up to 70%
Female Sexual Dysfunction has been linked to decreased vaginal blood flow and tissue sensitivity, which can be measured via Doppler studies, affecting over 50% of women with persistent symptoms
Approximately 45% of women aged 35-55 report some degree of FSD symptoms, highlighting its commonality in midlife women
Women with chronic illnesses like rheumatoid arthritis report higher rates of FSD, with prevalence up to 65%, largely due to physical and emotional factors
The rate of Female Sexual Dysfunction in women with depression is around 60-70%, illustrating the strong association between mental health and sexual function
Sexual inertness, or the absence of sexual activity, can be seen in approximately 20% of women with FSD, often associated with desire and arousal issues
Women with a history of pelvic surgery report higher prevalence of FSD, with rates up to 50%, related to tissue changes and psychological factors
The impact of Female Sexual Dysfunction also extends to economic costs, with direct medical expenses and lost productivity estimated at billions annually worldwide
Sexual activity and satisfaction are strongly linked to overall mental health and well-being, with women experiencing FSD more likely to report depression and loneliness

Prevalence and Impact of Female Sexual Dysfunction (FSD) Interpretation

Female Sexual Dysfunction affects millions of women worldwide—ranging from 10% in reproductive years to over 80% in older age—underscoring its ubiquity, yet its silent and stigma-shrouded nature means many suffer in silence, often without medical intervention, revealing that for many women, sexual health remains a perplexing and under-discussed chapter of their overall wellbeing.

Symptoms and Sexual Activity Patterns

Women experiencing menopausal symptoms report higher incidences of decreased libido and arousal, with up to 60% affected
The use of vaginal lubricants and moisturizers can alleviate symptoms of dryness associated with FSD, with up to 60-70% efficacy reported by users
The use of certain herbal supplements, such as ginseng and maca, has been associated with slight improvements in sexual desire among women, with response rates around 30-40%

Symptoms and Sexual Activity Patterns Interpretation

While up to 60% of menopausal women face decreased libido and arousal, the promising relief offered by lubricants, moisturizers, and herbal supplements—though variably effective—serves as a modest reminder that addressing female sexual dysfunction often requires a nuanced blend of science and self-care.